Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983494 | 0.89 | L3MBTL1 (0.37) | DPP4L3MBTL1FKBP1AMEN1KMT2A | |
| SCHEMBL26675619 | 0.85 | GBA1 (0.40) | DPP4CYP1A1 | |
| SCHEMBL13555502 | 0.83 | DPP4 (0.35) | DPP4 | |
| SCHEMBL22604561 | 0.82 | DPP4 (0.41) | DPP4L3MBTL1DRD2DRD3KCNH2 | |
| SCHEMBL609688 | 0.80 | L3MBTL1 (0.42) | L3MBTL1FKBP1ADRD2DRD3KCNH2 | |
| SCHEMBL25065916 | 0.79 | DPP4 (0.37) | DPP4DRD2DRD3KCNH2 | |
| SCHEMBL508355 | 0.79 | DPP4 (0.37) | DPP4DRD2DRD3KCNH2MEN1 | |
| SCHEMBL21325017 | 0.78 | DPP4 (0.36) | DPP4DRD2DRD3KCNH2 | |
| SCHEMBL9815020 | 0.78 | DPP4 (0.37) | DPP4POLB | |
| SCHEMBL16216346 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | DPP4 3829/4885L3MBTL1 4333/4885FKBP1A 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.